RecruitingPhase 2NCT05383742

Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis

Studying OBSOLETE: Tuberculous meningitis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Intervention
Rifampicin (RIF)(drug)
Enrollment
330 enrolled
Eligibility
15 years · All sexes
Timeline
20232029

Study locations (18)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05383742 on ClinicalTrials.gov

Other trials for OBSOLETE: Tuberculous meningitis

Additional recruiting or active studies for the same condition.

See all trials for OBSOLETE: Tuberculous meningitis

← Back to all trials